Bristol-Myers profit tops forecasts, helped by newer drugs

July 24 (Reuters) - Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.